Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy (IMAGE)

Weill Cornell Medicine

Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy

Caption

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues.

Credit

Weill Cornell Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.